Three Healthcare Stocks With Compelling Dividend Yields And Growth Rates

Published Wed, 16 Apr 2014 23:00 CET by DividendYields.org

The healthcare sector offers one of the best opportunities for investors. This is because health is not a luxury, and for some people it is a constant expense in their budgets.
Over the years, several companies have joined the market in different capacities and with various distinct target markets. While biotechnology companies are considered high reward speculative opportunities, large drug manufacturers like U.S.A’s Johnson & Johnson (NYSE: JNJ) and U.K’s GlaxoSmithKline (NYSE: GSK) offer stability and continuous payout in terms of dividends.
Over the last few years these two, along with Baxter International (NYSE: BAX), have shown resilience in their quest to grow dividends and maintain compelling yields. Now, these three form some of the most attractive dividend stocks in the healthcare sector.

Div Yield Div Growth (5 Yrs) Payout Ratio Exp Earnings Growth (1 yr) Exp Earnings Growth (5 yrs)
Johnson & Johnson 2.66% 7.49% 54% 7.72% 5.96%
GlaxoSmithKline 5.73% 4.23% 66% 9.26% 9.30%
Baxter International 2.67% 15.47% 52% 6.80% 7.45%
Johnson & Johnson
The U.S-based drug manufacturer offers investors a 2.66% dividend yield, based on its current stock price of $99.20 per share. This is after cruising 22.39% over the last 12 months.
Johnson & Johnson enjoys a wide economic moat, is well diversified and offers several products related to human health and hygiene. This provides the stability needed for dividend stocks, to prevent earnings and dividends from falling massively when one business segment performs poorly.
The company’s payout ratio of 54% is within the recommended threshold of not more than 60%, which means there is enough margin of safety to maintain a healthy dividend.
Johnson & Johnson earnings are expected to grow by 7.72% over the next 12 months, and at a compound annual growth rate “CAGR” of 5.96% over the next five years. In this case, the company’s expected 7.49% dividend growth rate for the next five years implies that, at some point, it might have to increase the payout ratio.

GlaxoSmithKline
GlaxoSmithKline is probably the most attractive dividend stock in the healthcare sector. The company offers compelling dividend yield of 5.73% and almost unmatched earnings growth rates for the next five years at 9.30%. Based on these figures, the company’s dividend yield is expected to grow by 4.23%.
GlaxoSmithKline earnings per share are expected to grow by 9.26% for the next one year.
Now, based on the company’s projected dividend growth rate compared to earnings growth rate, it appears as though the payout ratio could be cut significantly. This is positive for the company as it currently pays out 66% of its earnings as dividend, which is slightly above the recommended maximum rate.
Unlike Johnson & Johnson, GlaxoSmithKline’s price is only up about 5.95% over the last twelve months. However, its huge dividend yield has been a terrific example of how dividend stocks could differ from income stocks.

Baxter International
This is the smallest of the three healthcare giants. However, its market cap of more than $40 billion makes it a giant in its own respect. Therefore, it offers significant financial stability to investors.
When compared with is counterparts, Baxter International offers the best option for investors looking to reap more in term of dividends over the next five years. Its dividend is expected to grow by an average of 15.47% over the next five years. This means that the current quarterly dividend per share of $0.49 could rise to $0.56 next year.
The company’s payout ratio of 52% is also the best among the three companies. Baxter International operates in a slightly different industry from its two counterparts.
The medical instruments and supplies provider is also expected to enjoy significant earnings growth over the next five years at about 7.45% CAGR, which again is a clear signal for sustainable dividend payments.

Conclusion

12-Month Stock Price Graph
While GlaxoSmithKline offers the best dividend yield at current prices, Baxter International appears to be a compelling candidate for that tag in the coming years.
On the other hand, Johnson & Johnson enjoys wide economic moat and the best 12-month returns for those who might consider offloading some holding for cash, compared to GlaxoSmithKline’s 5.95%, and Baxter’s 3.47%.
Overall, they all appear to be some excellent dividend stocks to consider in 2014.


Stock name Dividend Yield
Glaxosmithkline 4.53
Johnson & Johnson 2.87
Baxter International 1.00

Articles featuring Glaxosmithkline (GSK):

Lanny's July Dividend Income Summary

We are in the thick of summer everyone! Are the dividends coming in hot and heavy? We will have to see my article below. The market has been volatile lately, as well as dividend increases. Let's see my July dividend income results below. Dividend Income I received a total of $571.18 of dividend income in July. A record July baby and getting closer to $1k for an off month. Additionally, my wife earned $87.24 this month and I am still debating on how to incorporate that into the analysis. I... Read more

Bert's July Dividend Income Summary

Looking back, July was a pretty monumental month for me. My daughter turned four months old, went to an in-home daycare for the first time, Cleveland hosted the MLB All Star Game, and it was my birthday! We talk about milestones on this website a lot. Although it wasn't an investing milestone, my birthday did represent another milestone that I won't talk about. But I am learning quickly that time does fly and things can happen in the blink of an eye. That's why today I am going to reflect on... Read more

5%+ Dividend Yield Portfolio: Grinding Along In 2019 (July 2019 Review)

Musings July 2019 was another month that was hard to predict as the market held its breath for the Fed rate decision. At the risk of sounding like a broken record, I again underperformed the S&P 500 (1.4% vs -0.8%), but this was my first month of splitting directions with the market in a negative way. For me, it is still a battle between my quest for bargains (meaning stocks and markets that have had a hard time of it) versus the market that continues to punish the unloved and froth the... Read more

5%+ Dividend Yield Portfolio: Coping With Existential Dread (May 2019 Review)

Musings May was a particularly weird month in a weird period for the markets (though I suppose that could be said about most times). The furious rally from the December 2018 lows (spurred by the narratives of a cool-headed Fed and Administration) fizzled spectacularly against the realities of extended valuations and partisan politics. Just how bad was it? (My advice is to have a drink before you look at your monthly statement this month - otherwise your tears might water down your... Read more

5%+ Dividend Yield Portfolio: The Number Of Stocks To Own (Apr 2019 Review)

Musings More than any single topic, I get a LOT of comments on my articles about ideal portfolio size (the age old ‘concentration vs. diversification’ debate). This is especially true of my extensive ETF holdings (about 50% of my total assets) where I own small pieces of many hundreds of companies. I suppose I’ve always tended to error towards over-diversification since I’ve internalized the ‘wisdom’ that I was taught as an undergraduate finance major about how diversification is the... Read more